Fundraise

MegaRobo raises $200M to push AI into real-world labs and factories

What's the deal? Chinese lab-automation company MegaRobo has raised nearly $200 million in a new round, led by the Oman Investment AuthorityDealroom has a profile for this one. Try Dealroom →. Existing backers Asia Investment CapitalDealroom has a profile for this one. Try Dealroom →, Granite AsiaDealroom has a profile for this one. Try Dealroom →, and Sinovation Ventures added to their stakes, with CMB International, Suzhou Venture Capital, and Sanjiang Zhaoshang Group joining.

What does it do? MegaRobo builds automation systems across two lines: smart labs for life-science research and smart manufacturing for semiconductors, optical interconnects, and displays. Its core platform, the Kunpeng Lab, functions as what the company calls a "data factory" for AI research, running automated wet-lab experiments around the clock.

By the numbers. Founded a decade ago, MegaRobo has now raised close to $600 million in total. As of June 2025, it reported an order backlog of US$206.3M. It has delivered infrastructure to more than 500 customers, including multinational pharma firms, CROs, and research institutions.

Why now? AI-for-science hinges on one problem: data. Scalable, high-quality, reusable research data is scarce, and most life-science labs cannot produce it consistently. Founder and chief executive officer Huang Yuqing frames it as a gap between "scientists' growing demand for data and relatively backward productivity" (translated from Chinese).

What's the endgame? The latest Kunpeng Lab splits research into two "brains" — one designs experiments from literature, the other executes them via robotic arms — forming a closed loop of AI design, autonomous experiment, real-world validation, and model learning. The platform recently advanced 31 drug-discovery pipelines in seven months. The company says the funding will expand core R&D and partnerships across China, Europe, North America, the Middle East, and Southeast Asia.

What could go wrong? Integration alone is not a durable moat. MegaRobo faces established lab-automation players such as TecanDealroom has a profile for this one. Try Dealroom → and Thermo Fisher, and its custom-project model carries thin margins and heavy cash burn. Its Hong Kong IPO application, filed in June 2025, lapsed later that year.

The signal: The round lands amid a broader embodied-intelligence funding wave; Reuters reported Chinese firms in the sector raised US$12.9B in the first half of 2026, roughly five times the year-earlier figure. For MegaRobo, the test is turning capital into repeatable, deployable products — proving value through customer adoption, not round size.

Read more: 36kr.com

Image credit: "Car Manufacturing Robotic Arms" by razvan.orendovici, licensed under CC BY 2.0

More top stories